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T- and natural killer (NK)-cell lymphomas are challenging childhood neoplasms. These cancers have varying presentations, vast
molecular heterogeneity, and several are quite unusual in the West, creating diagnostic challenges. Over 20 distinct T- and
NK-cell neoplasms are recognized by the 2008 World Health Organization classiﬁcation, demonstrating the diversity and
potential complexity of these cases. In pediatric populations, selection of optimal therapy poses an additional quandary, as
most of these malignancies have not been studied in large randomized clinical trials. Despite their rarity, exciting molecular
discoveries are yielding insights into these clinicopathologic entities, improving the accuracy of our diagnoses of these cancers,
and expanding our ability to effectively treat them, including the use of new targeted therapies. Here, we summarize this
fascinating group of lymphomas, with particular attention to the three most common subtypes: T-lymphoblastic lymphoma,
anaplastic large cell lymphoma, and peripheral T-cell lymphoma-not otherwise speciﬁed. We highlight recent ﬁndings
regarding their molecular etiologies, new biologic markers, and cutting-edge therapeutic strategies applied to this intriguing
class of neoplasms.
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INTRODUCTION
T-cell lymphomas encompass several hematological cancers
in children and adolescents. Arising in cells of the innate and
adaptive immune systems, T- and natural killer (NK)-cell neo-
plasms comprise over 20 distinct entities in the current World
Health Organization (WHO) schema (Table 1 and Figure 1).
1,2 The
most common types in pediatric patients are T-cell lymphoblastic
lymphoma (T-LBL) and anaplastic large cell lymphoma (ALCL).
Of the other rarely occurring pediatric T-cell neoplasms, peripheral
T-cell lymphoma-not otherwise speciﬁed (PTCL-NOS) is seen most
frequently. Most of these lymphomas are aggressive diseases
3 that
present formidable diagnostic and therapeutic challenges.
4 In this
review, we update the biologic features of several T-cell
lymphomas in children and adolescents, with a focus on their
molecular pathology and its implications for novel therapeutics.
T-LBL IN CHILDREN AND ADOLESCENTS
After Burkitt lymphoma, LBL is the second most common pediatric
non-Hodgkin lymphoma (NHL). In 80--90% of LBL, disease is
T-cell lineage, unlike acute lymphoblastic leukemia (ALL) where
precursor B-cell is typical. Thus, T-LBL is the most common
pediatric T-cell lymphoma.
5- -7 Historically, T-LBL and T-ALL have
been considered variant clinical manifestations of the same
disease, but genomic and gene expression studies reveal
molecular differences between T-LBL and T-ALL.
8,9 Clinical features
also subtly differentiate these cancers, with T-LBL tending to have
earlier and local relapses, and T-ALL more often having central
nervous system (CNS) involvement at diagnosis.
10- -12
Children with T-LBL frequently present with supra-
diaphragmatic mass. Overlapping symptoms in T-LBL and T-ALL
derive from their shared propensity to manifest with hepatic,
splenic, and nodal enlargement, as well as with mediastinal mass.
Serious sequelae from these clinical features can occur, including
obstructive airway compromise and superior vena cava syndrome;
both may require emergent glucocorticoid and/or radiation
therapy.
13 T-LBL is often advanced at diagnosis (stage III--IV),
unlike B-cell LBL, which primarily is a localized disease of
skin, bone, or lymph node. Accordingly, stage I and II T-LBLs are
relatively rare. As no molecular features can yet reliably
differentiate LBL from ALL, the clinical ﬁnding of X25%
of marrow inﬁltration by malignant lymphoblasts continues to
deﬁne ALL, while 5--25% marrow involvement is regarded
as stage IV LBL.
14
Current treatments for pediatric T-LBL
Children with limited disease (stage I--II) T-LBL do well, with
long-term overall survival (OS) of 85--90%.
5- -7,14 Disease-free
survival is lower at 63--73%, but relapsed patients show good
responses to salvage therapy.
15 As in advanced-stage T-LBL, ALL
protocols are the basis of treatment for T-LBL patients with
localized disease.
16 These patients are treated without local
surgery or radiation, and do not receive craniospinal radiation
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www.nature.com/bcjtherapy (CRT) prophylaxis. The following discussion will focus on
therapies for advanced (stage III--IV) T-LBL patients.
Advanced pediatric T-LBL outcomes improved dramatically on
the 10-drug LSA2L2 regimen.
17 Most LBL therapies can be traced
to this protocol, with nearly all current strategies comprised of
induction, consolidation, re-intensiﬁcation, and maintenance
phases. The speciﬁc timing and doses of some agents may vary,
but overall, treatments since 2000 have achieved 70--90% event-
free survival (EFS) with 12- to 24-month regimens (Table 2).
Many treatment protocols advanced LBL therapy over the past
15 years; highlights of these studies are brieﬂy summarized: The
German Berlin--Frankfurt--Munster (BFM)-90 regimen adminis-
tered CRT to all advanced patients, independent of CNS
involvement. Although EFS was 90% in stage III--IV patients,
long-term effects prompted ensuing studies to apply CRT to only
CNS-positive patients.
11 The Italian lymphoma non-Hodgkin
(LNH)-92 protocol reported only 69% EFS in advanced T-LBL, but
this regimen lacked re-intensiﬁcation, demonstrating the value
of this phase.
18 The BFM-95 study queried whether systemic
methotrexate (MTX) and intrathecal (IT) chemotherapy could
safely replace CRT as prophylaxis for CNS recurrence. Although its
84% EFS was lower than the 90% EFS of BFM-90, comparison with
other earlier BFM studies determined that omitting CRT was not
inferior to prior regimens that applied CRT to CNS-negative
patients.
19 The Children’s Oncology Group (COG) used an intense
and truncated (12-month) multi-agent protocol for advanced
T-LBL. This yielded a 78% EFS, similar to longer ALL-based
regimens.
20 Early reports from the current COG study testing high-
dose MTX and early intensiﬁcation suggest that neither interven-
tion improves EFS.
21
Two studies have explored completely omitting CRT in
advanced disease, including CNS-positive patients.
22,23 A
European Organization for Research and Treatment of Cancer
(EORTC) trial showed omission of CRT did not raise CNS relapse
rates, with 78% 6-year EFS. Although only three CNS-positive
patients participated in this trial, the overall low rate of CNS
relapse validates that intrathecal treatments can safely replace
CRT in stage III--IV, CNS-negative patients. This study also
identiﬁed response to a prednisone-only prephase as an
important prognostic factor. Patients in complete remission (CR)
after prephase (16/121 patients) had 100% EFS, but only 14% EFS
was seen in prednisone-resistant T-LBL.
22 St Jude’s NHL13 trial also
eliminated CRT. Like their institutional ALL regimen, NHL13 used
high-dose MTX every 8 weeks and added a re-induction phase
during maintenance. This study had an impressive 83% EFS in
advanced T-LBL, despite its lack of CRT.
23
Therapies for relapsed pediatric T-LBL
Historically, children with refractory or relapsed LBL have poor
prognoses, with 10% 5-year OS.
24 Most relapses occur within
2 years of diagnosis (Figure 2).
10 Successful outcomes have been
reported in recurrent T-LBL using intense re-induction chemother-
apy followed by either autologous (auto-) or allogeneic stem cell
transplant (allo-SCT), but these series each contained 10 or fewer
T-LBL patients, so reliable survival ﬁgures are not available.
25- -27
Modestly effective re-induction regimens include ICE (ifosfamide,
carboplatin, and etoposide; 92% response rate seen in a 40 patient
cohort containing 24 relapsed NHL) and DECAL (dexamethasone,
etoposide, cisplatin, high-dose cytarabine and L-asparaginase;
50% response rate in a 58 patient NHL cohort, including 26 LBL
cases).
28,29
Chemo-sensitive relapses have better outcome after auto or
allo-SCT.
28,30 Relapses after allo-SCT were less common in a group
of 204 LBL patients (most of whom had T-LBL), but higher
transplant-related mortality was felt to offset any survival
beneﬁt.
31 However, this remains an open question. In one
relapsed T-LBL BFM cohort, OS was quite low (14%; 4/28 patients),
but all 4 long-term survivors received allo-SCT. Yet, because only 2
patients received auto-SCT in this study (9 received allo-SCT and
17 chemotherapy-only), these data do not convincingly favor
allo- over auto-SCT.
10 However, other studies imply that graft vs
lymphoma effect after allo-SCT may help prevent relapses.
Speciﬁcally, one series of 53 refractory or recurrent LBL patients
showed much higher EFS after allo- compared with auto-SCT (40%
vs 4%).
32 A second study of 48 refractory or relapsed LBL patients
(32 with T-LBL) also demonstrated higher EFS and OS in the
allo-SCT group.
33 Although neither study examined T-LBL
exclusively, their large sample sizes and the preponderance of T-
cell disease within LBL both suggest that results are likely
generalizable to T-LBL.
Future therapies for pediatric T-LBL
To date, new therapies for T-LBL are limited. The novel purine
analog nelarabine shows promise in relapsed and refractory T-ALL,
but not T-LBL.
34 Impetus for the use of nelarabine in T-cell cancer
was suggested by the ﬁnding that purine nucleoside phosphor-
ylase-deﬁcient patients develop T-cell cytopenias because of toxic
deoxyguanosine triphosphate levels in T cells. As a deoxyguano-
sine triphosphate derivative, nelarabine resists purine nucleoside
phosphorylase-mediated degradation and shows marked
T-lymphocyte toxicity. In a phase II COG study, T-ALL patients in
ﬁrst relapse had a 55% response rate, and 48% of patients
achieved CR. Unfortunately, nelarabine lacked similar efﬁcacy
in T-LBL, and 18% of patients exhibited severe (X grade 3)
CNS toxicity, such as peripheral neuropathy, hallucinations, and
seizures.
34 Other novel agents targeting frequent NOTCH1 and
mammalian target of rapamycin (mTOR) kinase upregulation in
Table 1. WHO 2008 classiﬁcation of precursor and mature T/NK-cell
neoplasms
Leukemic or disseminated
T-lymphoblastic leukemia/lymphoma
T-cell prolymphocytic leukemia
T-cell large granular lymphocytic leukemia
Chronic lymphoproliferative disorders of NK cells
Aggressive NK-cell leukemia
Adult T-cell leukemia/lymphoma (HTLV1 positive)
Systemic EBV-positive T-cell lymphoproliferative disorders of
childhood
Extranodal
Extranodal NK/T-cell lymphoma, nasal type
Enteropathy-associated T-cell lymphoma
Hepatosplenic T-cell lymphoma
Extranodal-cutaneous
Mycosis fungoides
Sezary syndrome
Primary cutaneous CD30
+ lymphoproliferative disorders
Primary cutaneous anaplastic large cell lymphoma
Lymphomatoid papulosis
Subcutaneous panniculitis-like T-cell lymphoma
Primary cutaneous gamma-delta T-cell lymphoma
Primary cutaneous aggressive epidermotropic CD8
+ cytotoxic
lymphoma
Nodal
Angioimmunoblastic T-cell lymphoma
Anaplastic large cell lymphoma, ALK positive
Anaplastic large cell lymphoma, ALK negative
Peripheral T-cell lymphoma, NOS
Primary cutaneous small/medium CD4
+ T-cell lymphoma
Abbreviations: ALK, anaplastic lymphoma kinase; EBV, Epstein- -Barr virus;
HTLV1, human T-cell lymphotropic virus-1; NK, natural killer; NOS, not
otherwise speciﬁed; WHO, World Health Organization.
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also testing another purine nucleoside phosphorylase inhibitor,
forodesine, in T-cell malignancy. However, these trials investigate
adults with PTCL rather than pediatric T-LBL.
35
As salvage rates for relapsed T-LBL are dismal and promising
novel agents do not exist, delineating prognostic factors that
predict relapse would be useful in stratifying high-risk patients for
intensiﬁed upfront treatment regimens. Currently, such factors are
not well established in pediatric T-LBL. Aside from the striking
EORTC result where response to a 1-week prednisone pre-phase
predicted opposite extremes in EFS, other clinical prognostic
factors are lacking. Assessment of treatment responses via
laboratory testing, molecular studies, or radiographically (such as
2-deoxy-2-[18F]ﬂuoro-D-glucose positron emission tomography)
are all tenable options to identify high-risk patients early-on.
36
The paucity of cytogenetic and molecular features linked to
T-LBL clinical response presents intriguing opportunities for study.
One recent discovery is the ﬁnding that chromosome 6q loss
of heterozygosity in T-LBL predicts a higher risk of relapse, but
other cryptic karyotypic features may also exist.
8 Meanwhile, our
assessment of low-level minimal disseminated disease (MDD) and
minimal residual disease is also improving, with T-cell receptor
(TCR) PCR assays able to quantify these reliably.
37 Flow cytometry
can also detect occult disease, and these two techniques have
Figure 1. Montage of pathology images for several different T- and NK- cell lymphomas in children and adolescents. (a) T-LBL showing diffuse
inﬁltration of T-lymphoblasts with ﬁne nuclear chromatin and scarce cytoplasm. Blasts have inconspicuous nucleoli and irregular nuclear
contours.   200 magniﬁcation, hematoxylin and eosin (H&E) stain. (b) ALCL, ALK
þ, showing large neoplastic cells with marked pleomorphism
and abundant cytoplasm. Characteristic horseshoe-shaped cells are seen. Cells stained strongly with CD30 and ALK antibodies demonstrate a
mature T-cell immunophenotype.  400 magniﬁcation, H&E. (c) PTCL, NOS with predominantly large cell morphology. Neoplastic cells are
large with abundant cytoplasm and variably prominent nucleoli. Immunophenotyping reveals a mature T-cell phenotype, but cells lack
expression of CD30 or ALK.  400 magniﬁcation, H&E. (d) Hepatosplenic g/d T-cell lymphoma. Small-to-intermediate neoplastic cells have
inﬁltrated liver sinusoids. These cells show round nuclear contours, clumped chromatin without prominent nucleoli, and abundant clear
cytoplasm.  100 magniﬁcation, H&E. (e) SPTCL demonstrating invasion of malignant cells into fat. Small-to-intermediate size neoplastic cells
with moderate cytologic atypia and irregular nuclear contours surround fat lobules.  400 magniﬁcation, H&E. (f) Primary cutaneous g/d T-cell
lymphoma that presented with skin nodules and plaques with extensive dermal involvement and extension into panniculitic fat. Medium-to-
large neoplastic cells have occasional prominent nucleoli. Neoplastic cells lacked CD4 and CD8 expression and were EBV negative.  200
magniﬁcation, H&E. (g) T-cell post-transplant lymphoproliferative disorder in a patient with liver transplant 2 years prior. Clonal T cells have
invaded the intestine and are EBV positive.  400 magniﬁcation, H&E. (h) Extranodal T/NK-cell lymphoma of the nasal cavity showing
angiocentric pattern with vascular invasion. Neoplastic cells are small-to-intermediate in size with abundant cytoplasm. Irregular nuclei show
clumped hyperchromatic chromatin. Cells are CD8 and EBV positive.  200 magniﬁcation, H&E. (i) AITL with diffuse nodal effacement and
prominent arborizing vessels. Neoplastic cells are intermediate size and show variable clear cytoplasm.  200 magniﬁcation, H&E.
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of MDD and minimal residual disease in T-LBL.
38 In a separate
study using a 0.01% MDD threshold, two-thirds of patients had
MDD-positive marrow at diagnosis (Figure 3a). Critically, patients
with high marrow MDD had much lower 2-year EFS (52%)
than patients with o5% MDD (EFS¼89%; Figure 3b). These data
clearly demonstrate poor outcomes in stage III patients with
higher MDD.
39 However, prior BFM studies have shown no
prognostic difference between stage III and IV T-LBL patients.
19
Similarly, stage IV patients with gross marrow disease (6--24%
blasts) treated with COG-based therapy greatly exceed the poor
2-year EFS seen in these high-MDD stage III patients.
20 This curious
contradiction alludes to important questions that remain in T-LBL
biology. Further study of the aforementioned predictors and
discovery of new prognostic features will permit prospective
studies to determine which at-risk groups may beneﬁt from
intensiﬁed treatments, like allo-SCT, as ﬁrst-line approaches.
For instance, a new T-ALL type was recently described with
markedly poor prognosis, raising the question of whether this
group might also be relevant to T-LBL.
40 This new type, dubbed
early T-cell precursor ALL (ETP-ALL), has distinct biology from
classic precursor T-ALL. ETP-ALL retains stem-cell features and has
high genomic instability. In a cohort of over 200 T-ALL cases, over
12% met ETP-ALL criteria. These patients had higher minimal
residual disease during induction (Figure 4a) and increased rates
of induction failure and relapse (Figure 4b).
40 To optimally treat
these patients, St Jude’s now performs allo-SCT in ﬁrst remission
for ETP-ALL. Analyses of T-LBL specimens are needed to determine
if ‘ETP-LBL’ exists, and if so, whether a similar therapeutic strategy
might be warranted.
Molecular basis of T-cell lymphoblastic neoplasia and therapeutic
implications
Patients with T-LBL and T-ALL present similar challenges, so
understanding the molecular origins of these diseases is vital for
efforts to develop better treatment outcomes. It is generally
accepted that malignant transformation is a multistep process of
genetic mutations that arrest differentiation and allow uncon-
trolled cell growth.
41,42 In T-lymphoblastic cancers, these genetic
events have been queried extensively.
43,44 T-LBL and T-ALL share
some cytogenetic and molecular features, implying these diseases
are closely related neoplasms.
41 As most analyses of T-lympho-
blastic neoplasia have studied T-ALL, not all of this impressive
body of work may apply to T-LBL. However, efforts have been
undertaken to compare the genetic and genomic origins of these
related diseases, and they reveal both shared features and
potentially important differences.
45,46
Juxtaposition of the TCRb or TCRad enhancers with proto-
oncogenes via chromosomal translocations can mis-activate
many transcription factors or repressors.
47 Such TCR-driven
translocations are seen in about 33% of T-ALL cases, and
Table 2. Advanced disease lymphoblastic lymphoma in children
Cooperative Gp. BFM
11 BFM
19 St Jude
23 EORTC-CLG
22 AIEOP
18 CCG
20
Patients (N) 101 335 41 121 55 85
Protocol NHL-BFM-90 NHL-BFM-95 NHL13 CLG 58881 LNH-92 CCG 5941
Duration (months) 24 24 32 24 24 12
CRT All patients CNS+ only None None CNS+ only CNS+ only
CNS-- dose 0 or 12Gy
a NA None None NA NA
CNS+ dose 0, 18, or 24Gy
a 0, 12, or 18Gy
b None None 18Gy 18Gy
EFS (Est) 3-6 years 90% 84% 83% 78% 69% 78%
Abbreviations: AIEOP, Italian Association of Pediatric Hematology and Oncology; BFM, Berlin- -Frankfurt- -Munster; EORTC-CLG, European Organization for
Research and Treatment of Cancer-Children’s Leukemia Group; CCG, Children’s Cancer Group; CNS, central nervous system; CRT, cranial radiation therapy;
EFS, event-free survival; Est, estimate; LNH, lymphoma non-Hodgkin; NA, not applicable; NHL, non-Hodgkin lymphoma.
aOn BFM-90, children under 1 year
received no CRT, CNS+ children 1- -2 years received 18Gy, and CNS+ children X2 received 24Gy.
bOn BFM-95, children under 1 year received no CRT,
CNS+ children 1- -2 years received 12Gy, and CNS+ children X2 received 18Gy. Reprinted from Cairo.
5
Figure 2. Time and site of disease recurrence in children with relapsed lymphoblastic lymphoma. I, patients with T-LBL; X, patients with
precursor B-cell lymphoblastic lymphoma; BM, bone marrow. (*) Patient was treated on a high-risk arm and experienced relapse during an
intensive phase of treatment 11 months after start of therapy. Reprinted from Burkhardtet al.
10
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factors, LIM-only domain transcriptional regulators, or other
oncogenes like NOTCH1 and MYB. Non-TCR translocations are
also described which create oncogenic fusion proteins such as
MLL-ENL, CALM-AF10, and SET-NUP214.
48,49
Expression proﬁling in T-ALL supports the paradigm that
oncogenic transcription factors can disrupt the normal pathways
governing cell proliferation, differentiation, and survival during
T-cell development.
50- -52 As speciﬁc translocations and expression
patterns are associated with T-cell developmental arrest at distinct
stages, it is believed that these genetic events can deﬁne different
molecular subtypes of T-ALL.
44
However, two other common genetic lesions are present across
many T-ALL subtypes. The most prevalent genetic abnormality in
T-ALL is inactivation of CDKN2A and CDKN2B at chromosome
9p21. Deletions at this locus occur in 470% of T-ALL.
53 Another
frequent aberration is activating mutation(s) in the NOTCH1 proto-
oncogene, which are seen in over half of T-ALL cases.
54 Other rare
but recurrent genetic lesions in T-ALL include mutations activating
JAK1, FLT3, and RAS,
55- -57 or inactivating the tumor suppressors
NF1, PTEN, and WT1.
58- -60 Mutations in these genes are infrequent,
so it is not yet clear whether they occur in several T-ALL types like
CDKN2A/N2B and NOTCH1.
NOTCH1 activation is important to T-ALL pathogenesis. NOTCH1
normally promotes T-cell lineage commitment by lymphoid
progenitors,
61 and blocking its signaling in progenitors impedes
T-cell development, instead favoring the B-cell lineage.
62,63 A role
for NOTCH1 in T-ALL was ﬁrst suspected because of a rare
translocation, t(7;9)(q34;q34.3). This rearrangement coupled the
TCRb locus to ICN1, the IntraCellular portion of NOTCH1, a
constitutively active form of the protein.
64 NOTCH1’s role was
further substantiated by animal models where NOTCH1 and ICN1
can induce T-ALL and T-LBL in vivo.
65,66
Scrutiny of the NOTCH1 pathway has led to a novel therapeutic
strategy. Cell surface NOTCH1 undergoes proteolysis to generate
active ICN1, including a cleavage by the enzyme gamma-
secretase. Consequently, gamma-secretase inhibitors (GSIs) inhibit
NOTCH1 signaling (Figure 5). GSIs block growth in some T-ALL cell
Figure 3. Prevalence, degree, and impact of marrow involvement in children with T-cell lymphoblastic lymphoma (T-LL). (a) Percentage of T-LL
cells in bone marrow at diagnosis as detected by ﬂow cytometry, according to disease stage based on conventional criteria. Horizontal bars
indicate median value for each group. (b) Event-free survival stratiﬁed by level of T-LL cells in bone marrow at diagnosis as measured by ﬂow
cytometry: o5% and X5% T-LL cells. Reprinted from Coustan-Smith et al.
39
Figure 4. (a) Prevalence of minimal residual disease (MRD) during the early phases of therapy for patients with early T-precursor (ETP) vs
standard T-ALL. MRD levels were measured by ﬂow cytometry. Horizontal bars indicate median values, if above 0.01%. (b) Kaplan--Meier plots
showing cumulative incidence of remission failure or hematological relapse in patients with standard T-lymphoblastic leukemia (T-ALL; red) vs
early T-precursor (ETP-ALL; blue) treated on St Jude protocols. Curves start at time of diagnosis. Outcome estimates at 10 years of follow-up
are shown; P-values are from the log-rank test. Reprinted from Coustan-Smith et al.
40
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cells.
54,67 Added to glucocorticoids, GSIs show potent anti-T-ALL
effects in vivo, and also diminish the gastrointestinal toxicity
seen with GSIs alone. Combining GSIs with glucocorticoids can
also induce apoptosis in previously glucocorticoid-resistant
T-ALL.
68 Unfortunately, loss of the tumor-suppressor phosphatase
and tensin homolog deleted on chromosome 10 (PTEN) confers
GSI resistance to T-ALL cell lines.
59 However, as PTEN-null T cells
are highly sensitive to AKT inhibitors, combined NOTCH1 and
phosphatidylinositol 3-kinase (PI3K)/AKT therapies are also being
investigated in T-ALL.
59,69
Targeting of the mTOR pathway is similarly being explored,
as simultaneous GS- and mTOR-inhibition shows synergy in
T-ALL.
70,71 Similarly, because NOTCH1 regulates nuclear factor
kappaB (NF-kB) signaling, GSIs synergize with bortezomib, which
inhibits NF-kB (Figure 5).
72 Another target of NOTCH1 is CCR7,a
chemokine receptor that mediates CNS inﬁltration by T-ALL.
73 As
the CNS represents a relatively common site of relapse, GSIs may
be able to prevent CNS recurrence. Although promising, clearly, it
remains to be seen whether these ideas will improve T-ALL
outcomes, and if they can be extrapolated to T-LBL treatment.
CDKN2A/N2B and NOTCH1 mutations are prevalent in T-ALL, but
not universal. Thus, they fall short of an absolute molecular
explanation for all T-lymphoblast transformation. Given the vast
diversity of additional aberrations already described, it is likely that
other genetic lesions in T-cell malignancy are yet to be identiﬁed.
Certainly, future discoveries may generate further therapeutic
options. Notably, additional animal models of T-LBL offer
promising new tools to expand our knowledge of the molecular
basis of this disease.
66,74,75
ALCL IN CHILDREN AND ADOLESCENTS
ALCL comprises about 10% of pediatric NHL. It was recognized as
a distinct disease in the 1980s,
76 and much of its biology is now
understood.
77 ALCL has two presentations: systemic ALCL and
primary cutaneous ALCL occurring exclusively in skin.
78 Categor-
ized as a mature T-cell lymphoma, most ALCLs have TCR gene
rearrangements even if they lack T-cell antigen expression.
79
In children and adolescents, systemic ALCL is associated with
anaplastic lymphoma kinase (ALK) gene translocations, denoting
the disease as ALK
þ. The most common translocation creates an
Figure 5. Targeted treatment strategies for T-LBL. Glucocorticoid binding causes nuclear translocation of cytoplasmic receptors, which then
bind glucocorticoid response elements (GREs) to promote transcription of pro-apoptotic genes, leading to cell death. Other drugs block
pathways needed for growth and survival of malignant T-cell lymphoblasts. GSIs prevent release of intracellular notch (ICN1) from membrane-
tethered heterodimeric NOTCH1 protein. Combined glucocorticoid and GSI therapies show synergy, but pten deletions can subvert reliance
upon activated NOTCH1. Inhibitors of phosphatidylinositol 3-kinase (PI3K), AKT, and mTOR counteract this, thereby restoring GSI-sensitivity.
One of the activities of ICN1 is to augment NF-kB signaling. Blocking proteosomal degradation can stabilize inhibitors of NF-kB( I kB), allowing
Bortezomib to cooperate with GSI as well (ﬁgure design by Yaya Chu, New York Medical College).
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upstream to ALK. Less common translocations fusing ALK down-
stream of other partners are also described (Table 3).
80 Both
expression proﬁling and genomic analyses of ALCL suggest that
ALK
þ and ALK
  lymphomas actually represent distinct clinical
entities.
81,82 Accordingly, ALK
þ and ALK
  lymphomas are treated
differently and have differing prognoses. Apart from ALK
 
cutaneous ALCL, which can be successfully managed by surgery
alone, ALK
þ disease has better outcomes, and this distinction
stratiﬁes patients to receive less-intensiﬁed therapy.
ALCL is characterized histologically by large, pleomorphic, and
multinucleate ‘hallmark cells,’ with horseshoe nuclei, abundant
cytoplasm, and peri-nuclear eosinophilia.
83 Hallmark cells may
resemble Reed--Sternberg cells of Hodgkin lymphoma (HL), but
have less conspicuous nucleoli. Morphologic ALCL variants include
the common variant (75%) composed chieﬂy of hallmark cells, the
lymphohistiocytic variant (10%) with benign histiocytes admixed
with neoplastic cells, and a small cell variant (10%) of primarily
small neoplastic cells and only scattered hallmark cells.
84 Other
subtypes (o5%) include sarcomatoid, signet ring, neutrophil-rich,
and giant cell variants.
79
Pediatric and adult ALCL have several differences. Over 90% of
childhood ALCL is ALK
þ,
79 compared with only 60% of adult
ALCL.
85 Also, primary cutaneous ALCL is nearly always ALK
 , and
rare in children.
80 Children typically present with advanced stage
disease. A compendium of 225 childhood ALCL patients treated
on BFM, SFOP, or UKCCSG protocols revealed that 74% were stage
III--IV by St Jude criteria and 75% were Ann Arbor stage III or IV.
Extranodal disease was common (68%), with skin (26%), bone
(14%), and soft-tissues (15%) all relatively frequently involved.
86 B
symptoms were seen in 54%, consistent with prior reports.
86,87
Despite these aggressive features, both marrow and CNS invasion
are uncommon in pediatric ALCL, occurring in o10% and o5% of
cases, respectively.
85,86,88
Current treatments for pediatric ALCL
The optimal approach for limited disease is not established, as
both B-NHL and T-ALL regimens show similar efﬁcacy. EFS may be
as high as 100% for children with localized ALCL (stage I--II
resected) as shown in the NHL-BFM-90 trial using 2 months of
combined chemotherapy.
89 Previously, St Jude’s reported 75% EFS
in children with localized CD30
þ large cell lymphoma (presum-
ably ALCL) treated with three cycles of CHOP (cyclophosphamide,
doxorubicin, vincristine, and prednisone), either with or without
maintenance therapy.
90
Advanced pediatric ALCL treatment has evolved over the past
two decades. Different strategies have achieved 65--75% EFS with
either B-NHL protocols or LSA2L2-type therapies (Table 4).
89,91- -95
Other trials have used a doxorubicin, prednisone, and vincristine
(APO) backbone. Pediatric Oncology Group (POG)-9315 added
intermediate-dose MTX and high-dose cytarabine to APO, but this
did not improve efﬁcacy, with MTX and cytarabine causing greater
toxicity. Children on the APO-only arm had 75% 2-year EFS.
92 COG
is evaluating the addition of weekly vinblastine to APO. This
stems from encouraging French data in relapsed ALCL, where
Table 3. Recurrent chromosomal translocations involving ALK in cancers
Chromosomal
translocation
Partner protein Frequency
(%)
Fusion protein
(kDa)
Cellular
localization
Type of tumor Refs
t(2;5)(p23;q35) Nucleophosmin (NPM) 75- -80 NPM- -ALK (80) Nucleus, mucleolus
and cytoplasm
ALK
+ ALCL and ALK
+
DLBCL
193- -196
t(1;2)(q25;p23) Tropomyosin 3 (TPM3) 12- -18 TPM3- -ALK (104) Cytoplasm ALK
+ ALCL and IMT 197- -199
t(2;3)(p23;q21) TRK-fused gene (TFG) 2 TFG- -ALK (113,97,85) Cytoplasm ALK
+ ALCL 200, 201
inv(2)(p23;q35) ATIC 2 ATIC- -ALK (96) Cytoplasm ALK
+ ALCL and IMT 202- -204
t(2;17)(p23;q23) Clathrin heavy chain-like 1 (CLTC1) 2 CLTC1- -AKL (250) Granular cytoplasmic ALK
+ ALCL, IMT and
ALK
+ DLBCL
205- -207
t(2;X)(p23;q11- -12) Moesin (MSN) o1 MSN- -ALK (125) Cell-membrane
associated
ALK
+ ALCL 208, 209
t(2;19)(p23;p13) Tropomyosin 4 (TPM4) o1 TPM4- -ALK (95-105) Cytoplasm ALK
+ ALCL and IMT 198, 210
t(2;17)(p23;q25) ALO17 o1 ALO17- -ALK (ND) Cytoplasm ALK
+ ALCL 211
t(2l2)(p23;q13) or
inv(2)(p23;q11- -13)
RAN-binding protein 2 (RANBP2) o1 RANBP2- -ALK (160) Periphery of the
nucleus
IMT 212
t(2;22)(p23;q11.2) Non-muscle myosin heavy chain (MYH9) o1 MYH9- -ALK (220) Cytoplasm ALK
+ ALCL 213
t(2;11;2)(p23;p15;q31) Cysteinyl-tRNA synthetase (CARS) o1 CARS- -ALK (130) Unknown IMT 211, 214
ins(3’ALK)(4q22- -24) Unknown o1 Unknown Granular cytoplasmic ALK
+ DLBCL 215
t(2;4)(p23;q21) SEC31 homologue A (S.cerevisiae) (SEC31L1) o1 SEC31L1- -ALK (ND) Cytoplasm IMT 216
inv(2)(p21;p23) Echinoderm microtubule-associated
protein-like4 (EML4)
6 EML4- -ALK (ND) Unknown NSCLC 217
Abbreviations: ALCL, anaplastic large cell lymphoma; ALK, anaplastic lymphoma kinase; ALO17, ALK lymphoma oligomerization partner on chromosome 17;
ATIC, 5-aminoimidazole-4-carboxamide ribonucleotide formyltransferase/IMP cyclohydrolase; DLBCL, diffuse large B-cell lymphoma; IMT, inﬂammatory
myoﬁbroblastic tumors; ND, not determined; NSCLC, non-small-cell lung cancer; Refs, references. Reprinted from Chiarle et al.
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Table 4. Advanced anaplastic large cell lymphoma in children
BFM
89 POG
92 SFOP
91 St Jude
90 MSKCC
107 CCG
93 BFM, SFOP, and UKCCSG
86 EICNHL
98
Patients (N) 89 67 82 18 19 86 225 352
Protocol(s) NHL-BFM-90 POG 9315 HM89- -91 CHOP-based LSA2L2, LSA4 CCG-5941 BFM-86 and 90, SFOP HM89
and 91, and UKCCSG 9001-3
Modiﬁed NHL-BFM-90
Duration (months) 2- -5 12 7- -8 6- -18 14- -36 12 2- -8 4- -12
EFS (Est) 2- -5 years 76% 73% 66% 57% 56% 68% 69% 75%
OS 2- -5 years NR 93% 83% 84% 84% 80% 81% 94%
Abbreviations: BFM, Berlin- -Frankfurt- -Munster; CCG, Children’s Cancer Group; EICNHL, European Intergroup for Childhood NHL; EFS, event-free survival; Est,
estimate; MSKCC, Memorial Sloan Kettering Cancer Center; NHL, non-Hodgkin lymphoma; OS, overall survival; POG, Pediatric Oncology Group; SFOP, French
Pediatric Oncology Group; UKCCSG, United Kingdom Children’s Cancer Study Group. Adapted from Cairo.
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96 Unfortunately, a
recent COG report showed merely worse myelosuppression with
vinblastine, with an equivalent 77% 2-year EFS.
97
The European intergroup ALCL99 trial, which is based on the
BFM B-NHL treatment strategy, employed a less toxic regimen
with high-dose MTX and no IT therapy. They reported 74% 2-year
EFS and diminished toxicity.
98 Until ALCL99, CNS-negative ALCL
treatment usually included IT prophylaxis. With their recent
success in preventing CNS relapse without IT treatment, perhaps
reducing the number of high-dose MTX administrations should
also be considered. For rare ALCL patients with CNS disease, CRT
doses of 18--24Gy, in addition to high-dose MTX and/or
cytarabine plus IT chemotherapy, has been used.
89,91
Several prognostic factors have been identiﬁed in children with
ALCL. Clinical features associated with poor outcome include
visceral organ (liver, lung, or spleen) or mediastinal involvement,
elevated lactate dehydrogenase (LDH), and diffuse skin dis-
ease.
86,91,99 In addition, correlation between ALCL biology and
outcome is now possible via PCR-based MDD detection of the
NPM-ALK transcript. Higher levels of this mRNA in marrow
predicted a 71% chance of relapse, in contrast to 18% in MDD-
negative patients.
100 Meanwhile, detection of endogenous anti-
ALK antibodies are inversely correlated to ALCL dissemination and
risk of relapse in ALK
þ disease, implying that ALK may be a
potential immunotherapeutic target.
101,102 Additional results from
the recent ALCL99 trial reveal that two less common ALCL
variants, small cell and lymphohistiocytic, have a high risk of
treatment failure, independent of clinical risk factors.
103 Further
advances in our ability to identify patients at high risk for relapse
will enable appropriate application of intensiﬁed front-line
therapies to potentially improve outcomes.
Relapsed ALCL is quite different from other pediatric NHL
subtypes. Chemosensitivity of recurrent disease is a hallmark of
childhood ALCL, rendering salvage strategies generally effec-
tive.
104,105 Clinical behavior after relapse varies from aggressive to
indolent, with a waxing and waning course.
106 Historically, ALCL
has been considered prone to late relapse, like other lymphomas
seen in adult patients.
107 However, a recent report describing 74
children and adolescents with recurrent ALCL revealed a median
time of only 7.1 months between diagnosis and relapse. Of 58
patients who achieved remission after front-line therapy, only 18
recurred 41 year from original diagnosis.
108 The prognostic
signiﬁcance of early vs late ALCL relapse remains an open
question, with recurrences 41 year after diagnosis perhaps
having superior outcome,
96 but this ﬁnding has not been
consistent in all cohorts.
109 Late relapse again showed trends of
better EFS and OS in the most recent report,
108 but because these
studies all compile data from patient groups who received
differing initial treatments and relapse therapies, no deﬁnitive
answer is yet available.
In a series of three French clinical trials over two decades, relapse
therapies varied widely from single-agent vinblastine to multi-agent
treatment to fully ablative chemotherapy with auto- or allo-SCT.
Early relapses and failures with intensive initial regimens carry higher
risk for treatment failure. Three-year disease-free survival did not
differ in patients who received ablative SCT in CR2 vs chemotherapy
alone.
96,110 However, recent studies using allo-SCT in relapsed and
refractory ALCL are promising, with 75% 3-year EFS seen in one 20
patient cohort.
111,112
Progress in ALCL treatment lies in both new targeted agents
and optimizing risk stratiﬁcation to identify patients who may
beneﬁt from front-line allo-SCT. The CD30 antigen is one
compelling novel therapeutic target. Present in nearly all cases
of childhood and adolescent ALCL, CD30 expression is controlled
by ALK (Figure 6). SGN-35, an anti-CD30 monoclonal antibody, has
shown even greater success than its predecessor SGN-30.
113,114
Figure 6. Model of ALK and CD30 signaling. In ALCL, the NPM--ALK fusion protein governs CD30 expression by phosphorylating signal
transducer and activator of transcription 3 (STAT3). NPM--ALK also regulates extracellular signal-regulated kinase 1 (ERK1)- and ERK2-mediated
activation of JUNB protein. Phosphorylated STAT3 and activated AP1 complexes containing JUNB then cooperate to enhance CD30 tran-
scription. NPM--ALK impedes CD30 signaling and NFkB activation by sequestering tumor necrosis factor receptor-associated factor 2 (TRAF2)
away from CD30. This occurs via dimerization of NPM-ALK with wild-type (WT) NPM. CD30 engagement normally causes TRAF2 degradation.
Engagement of CD30 on ALCL cells results in activation of both the canonical and alternative NFkB pathways, which causes apoptosis and
p21-mediated cell-cycle arrest. A clinical trial is testing the use of anti-CD30 antibodies (red arrow) in ALCL109. Reprinted from Chiarle et al.
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refractory/recurrent CD30
þ ALCL and HL.
115 Dose-limiting toxi-
cities (thrombocytopenia, hyperglycemia, and febrile neutropenia)
were used to derive a treatment dose of 1.8mg/kg given every 3
weeks. At this dose, SGN-35 was generally well tolerated,
with patients exhibiting primarily grade 1 or 2 adverse effects
consisting of fatigue, nausea, neutropenia, and peripheral neuro-
pathy (33% of patients) as well as fever, headache, back pain, and
cough (25% of patients).
115 At higher doses, one trial showed 7/8
patients achieving CR. In a second trial, also at higher SGN-35
doses, 7/28 patients achieved CR with an overall response rate
(ORR) of 46%.
116,117 These responses to monotherapy in heavily
pre-treated patients offer exciting hope that adding SGN-35 to
combination therapy will yield even better results in front-line
therapy.
Development of other novel therapeutics has been fostered by
advances in understanding of ALCL biology. Targets include the
ALK protein itself, via small molecule and antibody-mediated
inhibition. The ALK inhibitor NVP-TAE684 both prevented tumors
and promoted pre-induced tumor regression in separate mouse
models.
118 Another kinase inhibitor, the dual MET/ALK inhibitor
Crizotinib, also shows promise in ALK
þ ALCL. Spurred on by the
ﬁnding that some non-small cell lung carcinoma patients have a
related translocation involving the ALK gene (EML4-ALK), Crizotinib
is being developed as a targeted agent for cancers driven by
constitutive ALK activity and was recently approved by the FDA in
patients with lung cancer with the presence of an ALK mutation.
Exciting results with this medication in refractory and relapsed
ALK
þ ALCL suggest this strategy holds great clinical promise.
119
These data with ALK inhibitors agree with ﬁndings that
circulating anti-ALK antibodies predict lower relapse rates, and
have led to vaccination studies using the ALK antigen.
120 Other
investigations have focused on different aspects of ALCL biology.
Although somatic mutations in ALCL are rare, sequencing
identiﬁed 6 different mutations in 12/44 (27%) patients with
ALK
þ ALCL. Perforin (PRF1) mutations were particularly prevalent
in ALCL, compared with control subjects where the A91V mutation
was infrequently seen (Po0.01).
121 PRF1 mutations occur in other
NHLs, and may impair cytotoxicity because of abnormal PRF1
conformation caused by the A91V mutation.
122 Additionally,
ampliﬁcation of the sonic hedgehog (SHH) gene in a subset
of ALK
þ ALCL
123 has been shown to lead to dysregulated SHH
signaling.
Proteomic analyses of ALCL complement these landmark
genomic studies and have been instrumental in understanding
the ALK protein network.
124,125 Proteomic signatures from cells
expressing the NPM--ALK fusion show alterations in cellular
processes including proliferation, ribosome synthesis, survival,
apoptosis, angiogenesis, and cyto-architectural organization.
124
Further studies revealed loss of cell adhesion caused by NPM-ALK
expression in a kinase-dependent manner, as well as sensitivity of
ALK
þ ALCL to inhibition of the RAS, extracellular signal-regulated
kinase (ERK) and FK506 binding protein-rapamycin-associated
protein (FRAP) mTOR signaling pathways.
124 Understanding the
myriad effects of NPM-ALK on these cellular pathways offers key
insights into ALK
þ ALCL biology.
Several potential therapeutic targets in ALCL have also been
identiﬁed by proteomic studies. Constitutive CD25 expression by
pediatric ALCL has led to in vitro investigations of the anti-CD25
agent, denileukin diftitox.
126,127 Identiﬁcation of other down-
stream pathways interconnected with ALK has led to studies
examining disruption of ALK-associated pathways. Heat shock
protein 90 (Hsp-90) and the PI3K/Akt pathway both have
interactions with the ALK protein network. In vitro studies
targeting Hsp-90 cause increased degradation of NPM-ALK and
apoptosis of ALCL cell lines,
128 while PI3K/Akt-null mice injected
with NPM-ALK
þ cells have impaired tumor formation.
129 These
advances in the genomics and proteomics of ALCL have enabled
new therapeutic approaches. Combining new and less-toxic
therapies offers exciting opportunities to enhance the efﬁcacy
and safety of therapies for future ALCL patients.
PTCL-NOS IN CHILDREN AND ADOLESCENTS
PTCLs are a heterogeneous group of cancers arising from mature T
and NK cells. These diseases include all forms of T-cell lymphoma
except T-lymphoblastic disease. PTCL-NOS is the second most
common PTCL after ALCL. In children, PTCL-NOS accounts for
about 1% of NHL cases.
130 In contrast, it comprises about 4% of
adult NHL.
131
The biology of PTCL-NOS shows great diversity. Identifying the
normal cells that correspond to the cellular origin of different
PTCL-NOS diseases has been challenging. Several pan-T-cell
antigens, as well as cytotoxic and activated T-cell markers, are
seen across different T-cell developmental stages.
132 Although
several cytogenetic abnormalities have been observed in
PTCL-NOS, a speciﬁc schema of clinically useful classiﬁcation has
not been established.
133 In fact, ALK translocations in ALCL
represent the only recurrent genetic aberration in PTCL.
134
Furthermore, apart from the frequent clonal TCR rearrangements
seen in PTCL-NOS, other molecular changes vary and display no
consistent pattern.
3
Recent studies in PTCL-NOS biology have led to exciting
ﬁndings. Genomic analyses of tumor specimens have linked
reduced expression of NF-kB genes to shortened survival.
135
Another report used expression proﬁling to stratify PTCL-NOS into
three subgroups: one notable for cyclin D2 expression, another
with NF-kB1 and BCL-2 overexpression, and a third with high
expression of genes in the interferon/Janus kinase/signal transdu-
cers and activators of transcription pathway.
136 Although further
studies are needed to conﬁrm these results and deepen our
understanding as pertains to lymphomagenesis, they represent
potentially important biological observations in PTCL-NOS.
The clinical presentations of PTCL-NOS can be as varied as its
biological characteristics. Patients often exhibit generalized
lymphadenopathy (frequently cervical) or extranodal disease of
the liver, spleen, skin, and marrow. Most patients have advanced
stage disease with high LDH at diagnosis, as well as B-symptoms
like fever, night sweats, and/or weight loss. These features derive
from increased cytokine production by malignant T cells, and can
even cause the hyper-inﬂammatory signs of hemophagocytic
syndrome.
3
Treatment strategies for PTCL, including PTCL-NOS, are
similarly varied. It has been challenging to develop and
establish effective regimens because clinical experience in
pediatric PTCL is sparse and individual studies are hampered by
too few patients. Overall, while a few PTCL types require unique
approaches (for example, adult T-cell leukemia/lymphoma
(ATLL) and Epstein--Barr virus (EBV)-positive T-cell lymphoproli-
ferative disease (T-LPD) of childhood, ALCL, and some cutaneous
entities), other PTCL patients receive similar therapies irrespective
of subtype.
The largest pediatric PTCL cohorts are studies from the USA and
the UK. The COG analyzed 20 pediatric patients over a 9-year
period. This cohort had 12 PTCL-NOS patients; other diagnoses
included extranodal NK/T-cell lymphoma nasal type, subcuta-
neous panniculitis-like T-cell lymphoma (SPTCL), and enteropathy-
type T-cell lymphoma. Treatments varied based upon clinical
staging. Advanced stage III--IV disease received a regimen of
doxorubicin, prednisone, vincristine, mercaptopurine, and MTX ±
alternating therapy with high-dose cytarabine and intermediate-
dose MTX. Localized stage I--II patients were treated with CHOP.
Patients with localized disease fared well; only 2 relapsed and 9/10
survived. In advanced disease cases, 6/10 relapsed and only
5 survived. These results are markedly better than typically seen in
adults with PTCL. However, while CHOP seems adequate for
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room for improvement.
137
The UK experience was similar. This study retrospectively
analyzed 25 PTCL cases in children and adolescents over 20
years. A similar distribution of PTCL subtypes was seen with 68%
categorized as PTCL-NOS. Remaining diagnoses included angio-
immunoblastic T-cell lymphoma (AITL), angiocentric PTCL, and
SPTCL. Patients received either B-NHL CHOP-like regimens or
T-ALL therapy. In children with PTCL-NOS, 9/12 survived after
T-ALL therapy, but 4/5 died following B-NHL treatment. Like the
COG study, when analyzed by extent of disease, most patients
(9/12) with local stage I--II disease survived, but only 6/12
advanced stage patients survived. The authors concluded that
T-ALL therapy was appropriate for children with PTCL-NOS, but
prognoses for children with advanced stage disease remain
guarded.
130
Adults with PTCL generally have inferior outcome. Five-year
OS in adult studies ranges from 25 to 45% with many treatment
strategies used.
3,138- -140 Chemotherapy regimens for adults
frequently include CHOP-like therapy, and incorporation
of cytarabine, cisplatin, and etoposide have not bolstered
survival rates. Owing to poor outcomes, high-dose chemotherapy
followed by auto- or allo-SCT has also been explored. High-dose
chemotherapy with auto-SCT has been attempted in both
the initial diagnosis and relapse setting. In patients with refractory
or recurrent disease, OS after auto-SCT is about 33%.
141
Some studies report slightly higher OS rates of 39--48%, but
these cohorts included ALCL patients, who typically do well
with auto-SCT salvage therapy. When separated out, non-ALCL
PTCL cases had OS closer to 30% in these same studies.
142
Attempts with front-line auto-SCT in newly diagnosed PTCL
have yielded only marginally better results. A large Italian study
in high-risk PTCL patients who received up-front auto-SCT
reported long-term OS rates of 39%. OS was hampered by the
fact that many patients progressed before auto-SCT and never
received transplant. But, in patients who did receive high-dose
chemo and auto-SCT, 12-year disease-free survival rate was
improved to 55%.
143
Allo-SCT has also been used in high-risk PTCL. This strategy
provides the advantages of infusing a known lymphoma-free
graft, as well as potential graft-vs-lymphoma effect. Although
patients receiving allo-SCT have proven lower relapse risks
(compared with auto-SCT), historically high rates of transplant-
related mortality in fully ablative conditioning regimens have
offset any survival advantage.
144 Better success has been achieved
using allo-SCT with reduced intensity conditioning regimens. In a
pilot study of 17 patients with refractory and recurrent disease
(eight after failed auto-SCT), 3-year progression-free survival was
64%, and only one patient experienced transplant-related
mortality.
145 These results offer hope for this notoriously
recalcitrant disease.
Establishing prognostic criteria for high-risk PTCL is important to
identify patients who may be candidates for intensiﬁed treatment.
As mentioned above, pediatric studies show patients with
advanced stage III--IV disease have markedly worse outcomes
than localized stage I--II disease.
130,137 In adults, the International
Prognostic Index (IPI) provides risk stratiﬁcation. The IPI incorpo-
rates features such as stage, LDH level, patient age, multifocal
extranodal disease involvement, and performance status. Its
validity in adult PTCL-NOS patients was veriﬁed in a Canadian
study of 117 patients. Those with an IPI score of 0--1 (30% of the
cohort) had 64% 5-year OS, while those with IPI 42 (70% of
patients) had OS of only 30%.
140 A Prognostic Index for PTCL-NOS
(PIT) model was established based on IPI principles and results
from a series of nearly 400 patients. Four variables were used to
stratify prognostic groups: age, performance, LDH, and marrow
involvement. Five-year OS rates by PIT score were: 0, 62%; 1, 53%;
2, 33%; and 42, 18%.
146 In applying this schema to pediatric
patients, advanced disease markers like high LDH and marrow
involvement would portend worse prognoses.
Considering the poor outcomes of high-risk PTCL patients, new
therapeutic strategies are desperately needed. Agents being
investigated include compounds from various pharmacological
classes including nucleoside analogs, antifolates, histone deace-
tylase and proteasome inhibitors, anti-angiogenesis agents, and
monoclonal antibodies. Of nucleoside analogs, pentostatin and
gemcitabine have been most promising. A single institution
study of 10 patients demonstrated 60% ORR to gemcitabine with
refractory/recurrent disease.
147 Nelarabine, on the other hand,
achieved only 11% ORR and showed marked toxicity.
148 The
histone deacetylase-inhibitor depsipeptide showed a 26% ORR in
a phase II trial,
149 and the anti-angiogenic bevacizumab has
induced CR in case reports of refractory/recurrent AITL.
150,151
Pralatrexate, an anti-folate, has shown promise in phase I--II trials
with 47% ORR in 26 patients with T-cell lymphoma, many with
PTCL-NOS.
152 This work has expanded to a multicenter trial, and
interim data show a 29% ORR in 65 patients, with 11% of patients
achieving CR.
153 Combining liposomal doxorubicin with the
proteasome inhibitor bortezomib has proven safe and effective
in other advanced hematological malignancies.
154 Proteasome
inhibitors promote apoptosis and other anti-proliferative proper-
ties by inhibiting the NF-kB pathway. Bortezomib thus is an
attractive candidate drug for PTCL-NOS diseases with demon-
strated overexpression of NF-kB1 target genes.
136 Bortezomib has
also been studied in refractory and relapsed cutaneous T-cell
lymphomas, where 67% ORR was seen with single-agent therapy.
Although most cases in that trial were mycosis fungoides, one
of two PTCL-NOS patients also responded.
155 Current efforts
add bortezomib to ﬁrst-line PTCL agents,
156 with in vitro testing
of cutaneous PTCL demonstrating synergy between bortezomib
and the histone deacetylase inhibitor suberoylanilide hydro-
xamic acid.
157
Monoclonal antibody therapies have gained considerable
momentum in the treatment of pediatric lymphomas over the
past decade. These successes have fostered interest evaluating
them in PTCL as well. Alemtuzumab is a humanized monoclonal
antibody targeting CD52, an antigen expressed on most
lymphocytes. It showed a 36% ORR as a single agent in a pilot
study of 14 patients with refractory/recurrent PTCL. However,
excessive infectious complications prompted premature closure of
this study after ﬁve patients suffered from treatment-related
mortality.
158 More recently, alemtuzumab was combined with
CHOP as front-line therapy. This regimen had 41% 1-year EFS, with
an acceptable toxicity proﬁle.
159 Other monoclonal antibodies
have been explored in cutaneous T-cell lymphomas and their
role in PTCL is unclear. These include the anti-CD4 antibody
zanolimumab, and the anti-CD25 antibodies daclizumab and
denileukin diftitox.
160,161 Despite this wide arsenal of novel
therapeutics and the guardedly optimistic results achieved by
reduced intensity allo-SCT in PTCL, it remains crucial to pursue
the biologic underpinnings of these diseases. Given their rare
occurrence, it is unlikely they will ever be amenable to large-scale
clinical trials to empirically test all possible therapies. It will
therefore continue to be important to identify biological markers
that provide scientiﬁc rationale to help guide treatment choices
that optimize therapeutic outcomes for this challenging and
diverse group of patients.
RARE T- AND NK-CELL LYMPHOMAS IN CHILDREN AND
ADOLESCENTS
A number of rare lymphomas originating from mature T and NK
cells account for an incredibly diverse spectrum of malignancies
(Figure 1).
162 These lymphomas vary widely by geography and
ethnicity with a considerably higher prevalence in Asia.
131
Although certain diseases have well-described etiologies
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and EBV in EBV
þ T-LPD), for most rare T- and NK-cell lymphoams,
a link is not determined.
3
Over 20 mature T- and NK-cell lymphomas are listed in Table 1.
The 2008 WHO Classiﬁcation of Lymphoid Neoplasms subdivides
T- and NK-cell lymphomas into four clinical presentation-based
groups: leukemic/disseminated, extranodal, extranodal-cutaneous,
and nodal. Among mature T- and NK-cell lymphomas,
the leukemic/disseminated group includes HTLV-1
þ ATLL and
systemic EBV
þ T-cell LPD of childhood. Extranodal diseases
include extranodal NK/T-cell lymphoma, hepatosplenic lympho-
ma, enteropathy-associated T-cell lymphoma, and others. Cuta-
neous forms include mycosis fungoides/Sezary syndrome, primary
cutaneous CD30
þ LPD (discussed previously with ALCL), SPTCL,
and primary cutaneous gamma/delta (g/d) T-cell lymphoma. Nodal
entities include ALCL, AITL, and PTCL-NOS. The remainder of this
review will discuss several rare T- and NK-cell lymphomas in
children and adolescents.
Hepatosplenic g/d T-cell lymphoma
Characterized by involvement of liver, spleen, and marrow,
hepatosplenic g/d T-cell lymphoma is a rare and aggressive
peripheral T-cell neoplasm. It is a disease of young adults
with distinct male predominance. Marked hepatosplenomegaly
with frequent marrow inﬁltration is typical, and patients
notably present without lymphadenopathy. Up to 20% of cases
arise in patients with chronic immune suppression, often after
solid organ transplantation or prolonged exposure to azathioprine
and inﬂiximab. Recently, EBV-negative T-cell lymphomas with
features of hepatosplenic T-cell disease were reported in
inﬂammatory bowel disease patients receiving inﬂiximab.
163
Karyotypic studies consistently show isochromosome 7q, often
with trisomy 8, and TCR rearrangements. Expression proﬁling
showed high levels of NK-cell messages such as killer cell
immunoglobulin-like and lectin-like receptors, compared with
PTCL specimens with a/b phenotype.
164 Ontology analysis
revealed enrichment of genetic pathways for cellular defense
responses, signal transduction, receptor activity, transmembrane
receptor activity, and immunoglobulin G binding. Prognosis is
grim, as most patients experience recurrent disease after brief
responses to conventional chemotherapy.
165 Long-term remis-
sions have been reported in pediatric and adult patients receiving
allo-SCT.
166,167
Subcutaneous panniculitis-like T-cell lymphoma
The characteristic presentation of subcutaneous lesions
distinguishes SPTCL. Although more common in adults,
there are several reports of SPTCL in children and adolescents.
Patients present with atypical T-cell inﬁltrations conﬁned to
subcutaneous tissues, resulting in panniculitic-appearing skin
nodules and/or ulcerated lesions. SPTCL is usually local, with
organ or node involvement uncommon. Clinical courses can
be protracted or aggressive, and patients may present with
symptoms of hemophagocytic syndrome.
168 T-cell phenotyping
has delineated two distinct entities. The a/b type is more common
and differs from the ominous primary cutaneous g/d
T-cell lymphoma. Cutaneous g/d disease has similar clinical
features to SPTCL, but is considered a variant of the hepatosplenic
g/d T-cell lymphomas discussed above. a/b SPTCL and
cutaneous g/d disease have different immunophenotypes
(a/b: CD8
þ56
 /bF1
þ; g/d: CD8
 56
þ/bF1
 ), and a/b disease has
less frequent features of hemophagocytosis and markedly better
outcome. Patients with a/b SPTCL have been treated with multi-
agent regimens with reasonable efﬁcacy, whereas patients
with cutaneous g/d disease have poor outcomes like cases of
g/d hepatosplenic lymphoma.
169
EBV-positive T-cell lymphoproliferative disorders
The 2008 WHO classiﬁcation incorporated two types of
EBV-associated T-cell LPD affecting the pediatric population:
systemic EBV
þ T-cell LPD of childhood and hydroa vaccini-
forme-like T-cell lymphoma. Both diseases occur predominantly in
Asians and individuals of Native American descent from various
regions of Latin America.
Systemic EBV-positive T-cell LPD of childhood
Most patients present with symptoms of a systemic hyper-
inﬂammatory response with disease mimicking the presentation
of hemophagocytic lymphohistiocytosis. Acute onset of fever and
malaise often precedes the eventual development of hepatosple-
nomegaly and liver failure, with or without lymphadenopathy. This
disease has rapid progression to multi-organ failure, hemophago-
cytic syndrome and death. Chronic active EBV infection has been
documented in some patients before developing EBV
þ T-cell LPD,
but most cases are fulminant and arise with acute primary EBV
infection. Fulminant cases are CD8
þ, whereas chronic active EBV-
associated cases are CD4
þ. EBV-encoded RNA-1 is positive in
neoplastic T cells that exhibit clonal TCR gene rearrangement and
harbor EBV in a clonal episomal form. This severe illness is
characterized by clonal proliferation of EBV-infected T cells with an
activated cytotoxic phenotype. All cases are type A EBV, with
either the wild type or a speciﬁc 30 base pair-deletion of the viral
LMP1 gene. Frequent sites of involvement include liver, spleen,
nodes, and marrow. The typical immunophenotype of tumor cells
is CD2
þCD3
þCD56
 . Transient chemotherapy responses are
reported, but almost all cases have rapid disease progression
ending in death.
170
Hydroa vacciniforme-like lymphoma
Hydroa vacciniforme-like T-cell lymphoma is an EBV
þ cutaneous
malignancy occurring mostly in children. Linked to sun sensitivity,
this condition primarily affects sun-exposed skin, and the face
in particular. Papulovesicular eruptions precede ulceration and
scarring. The clinical course is variable and skin lesions may be
recurrent. Late in the disease, systemic symptoms develop such as
fever, wasting, lymphadenopathy, and hepatosplenomegaly.
Similar to EBV
þ T-cell LPD, neoplastic cells have clonal TCR
rearrangements and harbor EBV in a clonal episomal form. It is not
clear whether the severe mosquito-bite allergy seen in chronic
active EBV infection, which has similar cutaneous lesions of NK-cell
derivation, is related to the hydroa vacciniforme-like lymphoma or
a distinct entity in the spectrum of EBV-associated disorders. Both
diseases are considered part of the spectrum of severe chronic
active EBV, demonstrating a broad variation in clinical aggressive-
ness.
171 Allo-SCT provides the only curative option for patients,
but it remains to be seen whether novel EBV-speciﬁc cytotoxic
T-lymphocyte (CTL) immunotherapies have a role in this unique
disorder.
172
Adult T-cell leukemia/lymphoma
ATLL is another rare T-cell malignancy associated with viral
infection. It is associated with HTLV-1 infection, a virus endemic to
regions including Japan, the Caribbean, parts of South America,
West and Central Africa, and some of the Oceanic Islands.
173
Infection with the HTLV-1 retrovirus carries an approximate 5%
lifetime risk of developing ATLL.
174 Although trophic for CD4
þ
T cells, HTLV-1 infection does not cause cytopathic destruction of
CD4
þ T cells. Rather, upon integration, it governs its own
transcription using its regulatory protein Tax. Tax interacts with
host proteins that can promote lymphomagenesis including the
NF-kB pathway,
175 trans-activating proteins that promote T-cell
proliferation and apoptosis inhibition, proteins repressing cell
cycle control and DNA repair, and multiple tumor suppressors.
176
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and T-cell proliferation pathways.
178 These retroviral proteins
contribute to HTLV-1 pathogenesis, but the virus itself is not
considered to be directly oncogenic. HTLV-1 infection induces
humoral and cellular immune responses, and like EBV-induced
lymphomas, impaired anti-HTLV-1 CTL responses are associated
with ATLL.
179- -181
There are four clinical variants of ATLL: acute, lymphomatous,
chronic, and smoldering. Acute is most common, with patients
presenting with disseminated disease, systemic symptoms,
organomegaly, and circulating malignant cells. The ATLL immu-
nophenotype is usually CD2
þ/4
þ/5
þ/25
þ, with loss of pan-T
marker CD7. CD8
þ variants also exist.
182 ATLL patients are
typically immunocompromised with increased risk of opportunis-
tic infection. Prognosis for acute and lymphomatous ATLL is
dismal with median survival o1 year using standard chemother-
apy.
183 Evidence for a link between HTLV-1 and ATLL
is substantiated by improved prognosis (30--40% survival) in
patients treated with allo-SCT.
184 Clearance of HTLV-1 proviral
loads and suggestion of a graft-vs-lymphoma effect have been
documented in multiple clinical trials, revealing promise for this
immunotherapeutic approach.
185
Extranodal NK/T-cell lymphoma
Extremely rare in the western hemisphere, extranodal NK/T-cell
lymphoma occurs primarily in Far and Southeastern Asia. The
majority of cases (60--90%) present with nasal or upper airway
masses, but extranasal disease is also described. Virtually all cases
are EBV
þ, with cytoplasmic CD3 and CD56 surface expression. Most
cases also test positive for cytotoxic proteins such as TIA-1,
granzyme B, and perforin.
186 Genomic proﬁling studies have shown
several genomic losses and gains associated with NK-cell malig-
nancies---deletion in 6q21 being most common.
187 Meanwhile,
expression proﬁling reveals high transcript levels for genes in the
p53 pathway, anti-apoptosis pathways, and cytokine receptors in
NK lymphoma cell lines as compared with normal NK cells. A
tandem mass spectrometry-based proteomic analysis established
overexpression of potential targets implicated in disease pathogen-
esis, including HSP90 and proliferating cell nuclear antigen.
Moreover, in vitro inhibition of HSP90 with geldanamycin
demonstrates reduced cell viability and increased apoptosis.
188
NK-cell lymphomas are very aggressive and have poor outcomes,
with 5-year OS of 32% in recent studies. Of note, extranasal NK
disease has strikingly worse prognosis (9% 5-year OS) vs the more
common nasal type (42% 5-year OS).
189
Angioimmunoblastic T-cell lymphoma
In contrast to the extranodal presentation of NK-cell lymphoma,
AITL usually presents with lymphadenopathy. Clinical hallmarks
include systemic disease features, with most patients manifesting
generalized lymphadenopathy, B symptoms, elevated LDH, and
hepatosplenomegaly. Many patients also present with pruritic skin
rash. EBV and human herpesvirus-6 are detectable in many cases,
but the implications of these ﬁndings are not clear.
190 Histologi-
cally, AITL is characterized by proliferation of high endothelial
venules and follicular dendritic cells. Tumors arise from CD4
þ cells
belonging to the follicular helper T-cell lineage.
191 Determination
of AITL molecular signatures has yielded a classiﬁer schema
comprised of three prominent patterns: a B-cell signature, a
follicular dendritic-cell signature, and a cytokine signature,
reﬂecting the relationship between the tumor cells and their
microenvironment. Gene expression analyses in AITL show
activation of the NFkB pathway and enrichment of genes
denoting dendritic cell function and interleukin-6 signaling.
Importantly, this study identiﬁed prognostic features predictive
of poor outcome in the form of gene signatures reﬂecting
immunosuppression: tolerogenic dendritic cells and CD31
 
stromal cells. Additionally, involvement of NFkB may provide a
potential means to develop novel treatments. Like extranodal NK-
cell lymphoma cases, AITL patients have poor survival outcomes
with 5-year OS approximating 30%.
192
Rare T- and NK-cell lymphomas summary
Ultimately, PTCL lymphomas remain a diagnostic and therapeutic
challenge. Although biologic studies have been performed in
adult series, the rarity of pediatric PTCL cases hinders large-scale
investigations on both the basic science and clinical fronts.
To address this problem, COG has initiated collection of rare
pediatric lymphomas and LPDs via study ANHL04B1. A central
institutional review board facilitates prompt patient enrollment
and expedited pathologic review of specimens to conﬁrm these
scarce diagnoses by a three-expert hematopathology panel. This
study also gathers information regarding therapy chosen by the
treating physicians and outcome. As these cases require
individualized care, no speciﬁc therapy is linked to the ANHL04B1
study. Instead, its aim is to collect diagnostic, treatment, and
outcome data on these rare diseases in children and adolescents.
Meanwhile, as new therapeutics are continually tested in adults, it
is likely that extrapolation from these studies will be necessary to
improve outcomes in rare pediatric cases. As our biologic
understanding of these diseases advances and new targets
emerge, therapies will become more enlightened. Until such
regimens have been proven, children with all subtypes of
advanced stage, refractory, and recurrent PTCL may beneﬁt from
induction therapy followed by allo-SCT with reduced intensity
conditioning regimens.
CONCLUSION
T- and NK-cell lymphomas in pediatric patients are a complex
group of neoplasms arising from precursor T lymphoblasts or
other mature T- and NK-cell subsets. T-LBL is the most common,
representing one-third of childhood and adolescent NHL.
Although the genomic and genetic underpinnings of T-ALL have
been thoroughly scrutinized, much less is known about T-LBL
molecular pathogenesis. It has been generally accepted that T-ALL
and T-LBL are different manifestations of the same disease, but
recent studies show that T-ALL and T-LBL have distinct genetic
aberrations and non-identical expression patterns. Advances in
T-ALL biology have led to novel therapeutics currently under
investigation, but a deeper understanding of T-LBL and its relation
to T-ALL is needed to enhance treatment outcomes for these
patients. Among mature T-cell neoplasms, ALK
þ ALCL is most
prevalent. The genetic aberration deﬁning this disease is, logically,
a target for therapeutic intervention. ALK tyrosine kinase inhibitors
are currently being tested in relapsed ALCL. Pediatric PTCLs arising
from mature T cells are so rare that they are challenging to study.
However, our increasing knowledge of their biologic features,
coupled with attention to adult treatment strategies, will
undoubtedly offer insights for pediatric PTCL. As our under-
standing of PTCL molecular pathogenesis continues to grow, there
is cause for optimism. Ultimately, there is no inherent reason
why childhood and adolescent T- and NK-cell lymphomas should
not be equally curable to other pediatric lymphocyte cancers like
HL, B-NHL, and ALL.
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